CoChat

B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms

Open access
Tran, Nancy H., Wu, Xiaochong, Frost, Jeffrey A. · 2005 · Journal of Biological Chemistry
Cited by 154

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

B-Raf is a key regulator of the ERK pathway and is mutationally activated in two-thirds of human melanomas. In this work, we have investigated the activation mechanism of B-Raf and characterized the roles of Ras and of B-Raf phosphorylation in this regulation. Raf-1 is regulated by an N-terminal autoinhibitory domain whose actions are blocked by interaction with Ras and subsequent phosphorylation of Ser338. We observed that B-Raf also contains an N-terminal autoinhibitory domain and that the interaction of this domain with the catalytic domain was inhibited by binding to active H-Ras. However, unlike Raf-1, the phosphorylation of B-Raf at Ser445 was constitutive and was only moderately increased by expression of constitutively active H-Ras or constitutively active PAK1. Ser445 phosphorylation is important to the B-Raf activation mechanism, however, because mutation of this site to alanine increased the affinity of the regulatory domain for the catalytic domain and increased autoinhibition. Similarly, expression of constitutively active PAK1 also decreased auto-inhibition. B-Raf autoinhibition was negatively regulated by acidic substitutions at phosphorylation sites within the activation loop of B-Raf and by the oncogenic substitution V599E. However, these substitutions did not affect the ability of the regulatory domain to co-immunoprecipitate with the catalytic domain. These data demonstrate that B-Raf activity is autoregulated, that constitutive phosphorylation of Ser445 primes B-Raf for activation, and that a key feature of phosphorylation within the activation loop or of oncogenic mutations within this region is to block autoinhibition. B-Raf is a key regulator of the ERK pathway and is mutationally activated in two-thirds of human melanomas. In this work, we have investigated the activation mechanism of B-Raf and characterized the roles of Ras and of B-Raf phosphorylation in this regulation. Raf-1 is regulated by an N-terminal autoinhibitory domain whose actions are blocked by interaction with Ras and subsequent phosphorylation of Ser338. We observed that B-Raf also contains an N-terminal autoinhibitory domain and that the interaction of this domain with the catalytic domain was inhibited by binding to active H-Ras. However, unlike Raf-1, the phosphorylation of B-Raf at Ser445 was constitutive and was only moderately increased by expression of constitutively active H-Ras or constitutively active PAK1. Ser445 phosphorylation is important to the B-Raf activation mechanism, however, because mutation of this site to alanine increased the affinity of the regulatory domain for the catalytic domain and increased autoinhibition. Similarly, expression of constitutively active PAK1 also decreased auto-inhibition. B-Raf autoinhibition was negatively regulated by acidic substitutions at phosphorylation sites within the activation loop of B-Raf and by the oncogenic substitution V599E. However, these substitutions did not affect the ability of the regulatory domain to co-immunoprecipitate with the catalytic domain. These data demonstrate that B-Raf activity is autoregulated, that constitutive phosphorylation of Ser445 primes B-Raf for activation, and that a key feature of phosphorylation within the activation loop or of oncogenic mutations within this region is to block autoinhibition. Raf proteins are Ras-regulated serine/threonine protein kinases that control the activation of the ERK 1The abbreviations used are: ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; CR, conserved region; RBD, Ras-binding domain; CRD, cysteine-rich domain; PAK1, p21-activated kinase-1; HEK, human embryonic kidney; HA, hemagglutinin; MBP, myelin basic protein; EGF, epidermal growth factor. 1The abbreviations used are: ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; CR, conserved region; RBD, Ras-binding domain; CRD, cysteine-rich domain; PAK1, p21-activated kinase-1; HEK, human embryonic kidney; HA, hemagglutinin; MBP, myelin basic protein; EGF, epidermal growth factor./MAPK cascade and, as such, control a basic mechanism by which cells respond to extracellular ligands (1Hagemann C. Rapp U.R. Exp. Cell Res. 1999; 253: 34-46Crossref PubMed Scopus (219) Google Scholar, 2Dhillon A.S. Kolch W. Arch. Biochem. Biophys. 2002; 404: 3-9Crossref PubMed Scopus (155) Google Scholar, 3Chong H. Vikis H.G. Guan K.L. Cell. Signal. 2003; 15: 463-469Crossref PubMed Scopus (344) Google Scholar, 4Peyssonnaux C. Eychene A. Biol. Cell. 2001; 93: 53-62Crossref PubMed Scopus (613) Google Scholar). They regulate ERK activation through the direct phosphorylation of MEK1 and MEK2, which then phosphorylate and activate ERK1 and ERK2. Once activated, ERKs phosphorylate a large number of cytoplasmic and nuclear substrates that enabl

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m501185200

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 154

Metadata

Authors
Tran, N. H., Wu, X., & Frost, J. A.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2005-04
Volume
280
Issue
16
Pages
16244-16253
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2140998787
Cited by
154
References
3
FWCI
1.84
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.